Navigation Links
Test quickly assesses whether Alzheimer's drugs are hitting their target
Date:4/9/2009

A test developed by physician-scientists at Washington University School of Medicine in St. Louis may help assess more quickly the ability of Alzheimer's drugs to affect one of the possible underlying causes of Alzheimer's disease in humans, accelerating the development of new treatments.

Scientists used the test to show that an Alzheimer's drug given to healthy volunteers reduced production of a substance known as amyloid beta (A-beta), a normal byproduct of human metabolism that builds to unhealthy levels forming brain plaques in Alzheimer's patients. The drug candidate, LY450139, which is also known as semagacestat, is being studied in clinical trials by Eli Lilly and Company.

Ongoing clinical trials are studying the effect that semagacestat may have on cognitive function and biochemical and brain imaging biomarkers in patients with Alzheimer's disease. Washington University researchers wanted to see whether the new measurement technique, stable isotope-linked kinetics (SILK), could detect the study drug's impact on A-beta synthesis in healthy volunteers.

"Bringing an Alzheimer's disease drug into clinical trials from tests in animal models has always been challenging," says study director Randall Bateman, M.D., a Washington University neurologist who treats patients at Barnes-Jewish Hospital. "We haven't had a way to quickly and accurately assess a drug's effects, and that meant there always had to be some degree of educated guesswork when it came to setting the optimal dosage for humans. SILK may help to eliminate much of that guesswork."

The results appear online in Annals of Neurology on April 10.

Scientists are unsure whether increased A-beta production, reduced clearance or a combination of the two lead to the A-beta buildup in the brain, a process that many believe triggers Alzheimer's disease. Bateman and his colleagues are currently using SILK to try to answer this question.

Until SILK, there has not been a way to directly measure the production or clearance of A-beta. The efficacy of potential new Alzheimer's drug candidates has been assessed by monitoring the cognitive functions of patients with the disease for extended periods of time, which require large, lengthy and expensive studies.

In their double-blind study, scientists gave 20 healthy volunteers varying doses of either a study drug or a placebo. At the start of the SILK test, volunteers were connected to an intravenous drip that gave them a slightly altered form of the amino acid leucine, which is a component of A-beta.

Over the course of several hours, cells in the brain picked up the labeled leucine and incorporated it into the new copies made of A-beta and other proteins. The scientists took periodic samples of the subjects' cerebrospinal fluid to determine how much of the A-beta included altered leucine.

Tracking the rise of the percentage of labeled A-beta over time reveals the A-beta production rate. Scientists then stop the leucine labeling but continue analyzing spinal fluid samples. As the body removed old A-beta and made new A-beta, the percentage of A-beta containing altered leucine dropped, revealing the A-beta clearance rate.

The results suggest a dose-dependent drop in A-beta production, with an 84 percent reduction in A-beta production being measured with the highest study drug dose.

The SILK procedure takes 36 hours, but provides scientists a more detailed assessment of amyloid beta production and clearance levels than they can obtain through conventional methods.

"You could use a spinal tap to look directly at the amount of A-beta present in the cerebrospinal fluid, but we've shown that natural processes cause A-beta levels to change dynamically," says Bateman. "Such changes make it more difficult to assess the effects of a drug in that fashion."


'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University in St. Louis
Source:Eurekalert

Related medicine news :

1. Twinkle after effect can help retinal patients detect vision loss quickly and cheaply
2. Twinkle After-Effect Can Help Retinal Patients Detect Vision Loss Quickly and Cheaply and Prevent Further Loss
3. Mercury in Childhood Vaccines Excreted Quickly
4. MITs PANTHER sensor quickly detects pathogens
5. Huron Capital Moves Quickly To Expand O&P Business
6. Historic Fundraising Initiative to Empower Women & Girls Worldwide Reaches $100 Million Quickly Even as U.S. Economy Slows
7. Women Who Quit Smoking Lower Heart Risks Quickly
8. Boosting Brain Protein Quickly Cut Excessive Drinking
9. Brain Scans Detect Alzheimers Disease Quickly
10. Age-related memory loss tied to slip in filtering information quickly
11. Michigan Business & Professional Association Urges Legislature to Act Quickly on Individual Health Care Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... (PRWEB) , ... April 23, 2017 , ... ... and managed services announced the achievement of Cisco Select certification and SMB specialization. ... the United States. , In earning the Select Certification, Altura fulfilled ...
(Date:4/22/2017)... , ... April 22, 2017 , ... The San Juan Capistrano summer camp ... parenting report outlining the need for summer camps to provide physical activities for all campers. ... Physical Activity In Summer Camps , With an increase in specialty camps that focus on ...
(Date:4/21/2017)... ... , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , has ... bony lump located on the forehead usually attributed to a facial fracture. Their appearance ... Dr. Shah has discovered an approach that is minimally invasive. He is an expert ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
(Date:4/21/2017)... Sterling, VA (PRWEB) , ... April 21, 2017 ... ... hosting its first weeklong campaign, AWARE: A Week of Addiction and Recovery Education, ... emerging evidence in treating and preventing substance use disorders. , The mission ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology: